Longboard Pharmaceuticals Alpha and Beta Analysis
| LBPHDelisted Stock | USD 59.98 0.00 0.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Longboard Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Longboard Pharmaceuticals over a specified time horizon. Remember, high Longboard Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Longboard Pharmaceuticals' market risk premium analysis include:
Beta (1.32) | Alpha 1.02 | Risk 7.66 | Sharpe Ratio 0.18 | Expected Return 1.39 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Longboard |
Longboard Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Longboard Pharmaceuticals market risk premium is the additional return an investor will receive from holding Longboard Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Longboard Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Longboard Pharmaceuticals' performance over market.| α | 1.02 | β | -1.32 |
Longboard Pharmaceuticals Fundamentals Vs Peers
Comparing Longboard Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Longboard Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Longboard Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Longboard Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Longboard Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Longboard Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Longboard Pharmaceuticals to competition |
| Fundamentals | Longboard Pharmaceuticals | Peer Average |
| Return On Equity | -0.47 | -0.31 |
| Return On Asset | -0.31 | -0.14 |
| Current Valuation | 2.06 B | 16.62 B |
| Shares Outstanding | 34.44 M | 571.82 M |
| Shares Owned By Insiders | 1.19 % | 10.09 % |
| Shares Owned By Institutions | 98.81 % | 39.21 % |
| Number Of Shares Shorted | 1.93 M | 4.71 M |
Longboard Pharmaceuticals Opportunities
Longboard Pharmaceuticals Return and Market Media
The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 10/04/2024 |
2 | LBPH Stock Alert Halper Sadeh LLC Is Investigating Whether the Sale of Longboard Pharmaceuticals, Inc. Is Fair to Shareholders | 10/14/2024 |
3 | Traders Buy High Volume of Longboard Pharmaceuticals Call Options | 10/15/2024 |
4 | Longboard Pharmaceuticals Downgraded by Wedbush to Hold | 10/16/2024 |
5 | Longboard Pharmaceuticals Rating Reiterated by B. Riley | 10/18/2024 |
6 | Vanguard Group Incs Strategic Acquisition in Longboard Pharmaceuticals Inc | 11/05/2024 |
7 | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | 11/07/2024 |
8 | Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies | 11/12/2024 |
9 | Acquisition by Kaye Randall of 30554 shares of Longboard Pharmaceuticals at 6.0 subject to Rule 16b-3 | 11/19/2024 |
10 | Longboard Pharmaceuticals concludes merger with H. Lundbeck AS | 12/02/2024 |
About Longboard Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Longboard or other delisted stocks. Alpha measures the amount that position in Longboard Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Longboard Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Longboard Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Longboard Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Longboard Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Longboard Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Longboard Pharmaceuticals' management manipulating its earnings.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Longboard Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Longboard Stock
If you are still planning to invest in Longboard Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Longboard Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |